clinical trial · NCT05199584
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.·phase2·completed·n = 20
Solid Tumors With PTCH1 Loss-of-function MutationsENV-101 (taladegib)
brief summary
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.
started
May 24, 2022
primary completion
Feb 20, 2024
completion
Feb 20, 2024
last updated
Mar 5, 2026
official title
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol